Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Li, Siming ^a   Kong, Yan ^a   Si, Lu ^a   Chi, Zhihong ^a   Cui, Chuanliang ^a   Sheng, Xinan ^a   Guo, Jun ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Clinical response; Mammalian target of rapamycin; Metastatic renal cell carcinoma; Predictive biomarker; Targeted therapy

Indexed keywords

BIOLOGICAL MARKER; EVEROLIMUS; INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEIN S6; ANTINEOPLASTIC AGENT; EIF4EBP1 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; PHOSPHOPROTEIN; PROTEIN KINASE INHIBITOR; RAPAMYCIN; RIBOSOMAL PROTEIN S40; RIBOSOME PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE; TUMOR MARKER;

ADRENAL METASTASIS; ADULT; ARTICLE; BONE METASTASIS; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY METASTASIS; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MULTICENTER STUDY; MUSCLE METASTASIS; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; CHINA; DISEASE FREE SURVIVAL; ENZYMOLOGY; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHOSPHORYLATION; PREDICTIVE VALUE; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CHINA; CLINICAL TRIALS, PHASE I AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDIVIDUALIZED MEDICINE; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PATIENT SELECTION; PHOSPHOPROTEINS; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RETROSPECTIVE STUDIES; RIBOSOMAL PROTEINS; SIROLIMUS; TIME FACTORS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84901951157     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-376     Document Type: Article

References (24)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
2. Dancey J. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 2010, 7:209-219. 10.1038/nrclinonc.2010.21, 20234352.
3. Powles T, Chowdhury S, Jones R, Mantle M, Nathan P, Bex A, Lim L, Hutson T. Sunitinib and other targeted therapies for renal cell carcinoma. Br J Cancer 2011, 104:741-745. 10.1038/sj.bjc.6606061, 3048200, 21266975.
4. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010, 116:4256-4265. 10.1002/cncr.25219, 20549832.
5. Yoshizawa A, Fukuoka J, Shimizu S, Shilo K, Franks TJ, Hewitt SM, Fujii T, Cordon-Cardo C, Jen J, Travis WD. Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. Clin Cancer Res 2010, 16:240-248. 10.1158/1078-0432.CCR-09-0986, 20008839.
6. No JH, Jeon YT, Park IA, Kim YB, Kim JW, Park NH, Kang SB, Han JY, Lim JM, Song YS. Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer. Gynecol Oncol 2011, 121:8-12. 10.1016/j.ygyno.2010.12.364, 21276607.
7. Molinolo AA, Hewitt SM, Amornphimoltham P, Keelawat S, Rangdaeng S, Meneses García A, Raimondi AR, Jufe R, Itoiz M, Gao Y, Saranath D, Kaleebi GS, Yoo GH, Leak L, Myers EM, Shintani S, Wong D, Massey HD, Yeudall WA, Lonardo F, Ensley J, Gutkind JS. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 2007, 13:4964-4973. 10.1158/1078-0432.CCR-07-1041, 17785546.
8. Guo J, Huang Y, Zhang X, Zhou F, Sun Y, Qin S, Ye Z, Wang H, Jappe A, Straub P, Pirotta N, Gogov S. Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study. BMC Cancer 2013, 13:136. 10.1186/1471-2407-13-136, 3626915, 23514360.
9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
10. Kong Y, Si L, Zhu Y, Xu X, Corless CL, Flaherty KT, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lu A, Guo J. Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 2011, 17:1684-1691. 10.1158/1078-0432.CCR-10-2346, 21325067.
11. Darwish OM, Kapur P, Youssef RF, Bagrodia A, Belsante M, Alhalabi F, Sagalowsky AI, Lotan Y, Margulis V. Cumulative number of altered biomarkers in mammalian target of rapamycin pathway is an independent predictor of outcome in patients with clear cell renal cell carcinoma. Urology 2013, 81:581-586. 10.1016/j.urology.2012.11.030, 23290145.
12. Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, Youmans A, Polivy A, Mandato L, McDermott D, Stanbridge E, Atkins M. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2007, 5:379-385. 10.3816/CGC.2007.n.020, 17956710.
13. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289-296. 10.1200/JCO.20.1.289, 11773181.
14. Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP. A phase 2 study with a daily regimen of the oral mTOR inhibitor EVEROLIMUS (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009, 115:2438-2446. 10.1002/cncr.24280, 19306412.
15. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456. 10.1016/S0140-6736(08)61039-9, 18653228.
16. Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J, Mueller M, Fumagalli S, Kozma SC, Thomas G. S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol Cell Biol 2004, 24:3112-3124. 10.1128/MCB.24.8.3112-3124.2004, 381608, 15060135.
17. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004, 23:3189-3199. 10.1038/sj.onc.1207545, 15094768.
18. Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy DC, Miller WH, Borden KL. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood 2009, 114:257-260. 10.1182/blood-2009-02-205153, 19433856.
19. Konicek BW, Stephens JR, McNulty AM, Robichaud N, Peery RB, Dumstorf CA, Dowless MS, Iversen PW, Parsons S, Ellis KE, McCann DJ, Pelletier J, Furic L, Yingling JM, Stancato LF, Sonenberg N, Graff JR. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res 2011, 71:1849-1857. 10.1158/0008-5472.CAN-10-3298, 21233335.
20. Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, Petroulakis E, Robichaud N, Pollak M, Gaboury LA, Pandolfi PP, Saad F, Sonenber N. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A 2010, 107:14134-14139. 10.1073/pnas.1005320107, 2922605, 20679199.
21. Graff JR, Konicek BW, Lynch RL, Dumstorf CA, Dowless MS, McNulty AM, Parsons SH, Brail LH, Colligan BM, Koop JW, Hurst BM, Deddens JA, Neubauer BL, Stancato LF, Carter HW, Douglass LE, Carter JH. eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res 2009, 69:3866-3873. 10.1158/0008-5472.CAN-08-3472, 19383915.
22. Sun CH, Chang YH, Pan CC. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology 2011, 58:1054-1063. 10.1111/j.1365-2559.2011.03856.x, 21707707.
23. Nawroth R, Stellwagen F, Schulz WA, Stoehr R, Hartmann A, Krause BJ, Gschwend JE, Retz M. S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer. PLoS One 2011, 6:e27509. 10.1371/journal.pone.0027509, 3216974, 22110663.
24. Wislez M, Spencer ML, Izzo JG, Juroske DM, Balhara K, Cody DD, Price RE, Hittelman WN, Wistuba II, Kurie JM. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res 2005, 65:3226-3235.